Gemcitabine based trimodality treatment in patients with muscle invasive bladder cancer: May neutrophil lymphocyte and platelet lymphocyte ratios predict outcomes?

CONCLUSION: Gemcitabine based trimodality treatment is well-tolerated with similar oncologic outcomes reported in the literature. Older age, presence of CIS and high NLR and PLR values seem to deteriorate DSS. PMID: 33189528 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33189528?dopt=Abstract

Source: Urologic Oncology - November 11, 2020 Category: Urology & Nephrology Authors: Hurmuz P, Ozyigit G, Kilickap S, Esen CSB, Akdogan B, Ozen H, Akyol F Tags: Urol Oncol Source Type: research